- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Coherus Announces Strong Early Sales for Pegfilgrastim Biosimilar, Udenyca
In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
Coherus BioSciences, maker of the pegfilgrastim biosimilar Udenyca, has announced its preliminary unaudited sales for the first quarter of 2019. In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
The company says that it will discuss its sales in further detail after the data are reported in its Form 10-Q for the quarter, and it will provide additional financial updates on May 9, 2019.
The biosimilar developer brought its pegfilgrastim biosimilar to the US market on January 3, 2019, with a comprehensive launch that included 340B hospitals and non-340B hospitals and clinics. The company launched the product at a list price of $4175 per unit, or a 33% discount to the reference pegfilgrastim, Neulasta. Udenyca’s list price matches that of Mylan’s Fulphila, the first pegfilgrastim biosimilar to launch in the United States, although these list prices do not reflect any rebates that may be provided by the respective drug makers.
The early sales numbers for the biosimilar pegfilgrastim reflect the success of what Coherus’ president and chief executive officer, Dennis M. Lanfear, has called the company’s “branded approach” to the product’s launch.
During the recent 37th Annual J.P. Morgan Healthcare Conference, Lanfear said that “Our approach is that of a branded launch…this has never been done before with a biosimilar.” This strategy involves a focus on payers, integrated delivery networks, and group purchasing organizations that consolidate purchasing for clinics and hospitals, as well as provider segments comprising community oncology clinics, 340B hospitals, and non-340B hospitals, he explained.
In addition to Udenyca, Coherus is currently advancing 2 additional late-stage biosimilar programs: an adalimumab biosimilar referencing Humira and an etanercept biosimilar referencing Enbrel. It is also developing ophthalmology biosimilars, including ranibizumab, referencing Lucentis, and aflibercept, referencing Eylea. It is also developing CHS-131, a novel small-molecule agent that is intended to treat both nonalcoholic steatohepatitis and multiple sclerosis.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
